As AR inhibitor ENZ is known to induce t-NEPC, we first exposed LNCaP and C42B prostate cancer cells to ENZ and monitored the expression of DPYSL5 and neuronal lineage markers every three days over a total of twelve days. Here, DPYSL5 is linked to prostate cancer.